Collectively, these results indicate that CDK2 is a potential therapeutic target for letrozole re-sensitization, while co-targeting CDK6 might be required to suppress a secondary mechanism of resistance in CDK6, p-CDK2 and/or cyclin E1 upregulated resistant ER+ BC cells. The gene discussed is CCNE1; the disease is breast cancer.